Valion Bio Fires General Counsel; Entolimod Advances to Fully Funded AFRRI Efficacy Study
VBIO is trading near its 52-week low of $0.524 (12% above the low) on light trading volume (0.1× avg).
Summary
Valion Bio disclosed the termination of General Counsel Melinda Lackey effective October 30, 2026, with a $26,750 severance, and announced that AFRRI will run a fully funded Entolimod efficacy study in GI-ARS with top-line results expected in early December.
Key Events · Executive and Board Changes · VBIO
-
General Counsel Terminated
Valion notified Melinda Lackey, General Counsel and SVP of Legal Affairs, of termination on October 27, 2026, effective October 30, 2026.
-
Severance Terms Disclosed
Separation Agreement dated October 31, 2026 provides a $26,750 gross lump-sum payment plus COBRA premiums through November 30, 2026; Lackey forfeits unvested equity and releases all claims.
-
Open Legal Matters Handed Off
The agreement requires Lackey to transfer a list of open matters including the Bexar County lawsuit (Snell), the CG Capital / Rich matter, patent counsel matters (Dentons, Launchpad, Snell), the Handley proxy item and pending 8-Ks.
-
Entolimod Moves to Efficacy Study
AFRRI will evaluate Entolimod in a GI-ARS therapeutic efficacy model, fully funded by NIAID/RNCP under an Interagency Agreement with USU/AFRRI; top-line survival results are anticipated in early December.
Analysis · VBIO · Life Sciences
Valion is losing its top legal officer at a moment when it is juggling a Bexar County lawsuit, a CG Capital/Rich matter, patent counsel work and a proxy fight — the separation agreement itself lists those open matters as handoff items. The $26,750 severance is trivial in dollar terms, but the timing and the breadth of open legal matters make the departure a governance concern rather than a routine exit. The offsetting news is that NIAID's Radiation and Nuclear Countermeasures Program elected to move Entolimod into a fully funded therapeutic efficacy study at AFRRI, with top-line survival data expected in early December. That study costs Valion nothing and produces the next binary readout on its lead asset, which matters for a company that previously disclosed going-concern doubt and cash of just $2.1M at June 30.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.52 to $67.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.